Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prostalene
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
Prostalene is a synthetic analog of prostaglandin F2 alpha. It is classified as a small molecule and is primarily used in veterinary medicine for the control of estrus (heat) in mares. Its mechanism of action involves acting as an agonist at the prostaglandin F2 alpha receptor (PTGFR), leading to luteolysis and subsequent estrus synchronization in horses. Prostalene is administered by subcutaneous injection at a dose of 5 micrograms per kilogram body weight for this indication[2][3][5][7].
- Brand names
- Synchrocept
- Other names
- prostalenoprostalenum54120-61-5
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on prostalene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prostalene.